Equillium Inc

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.

Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis (UC).

Equillium's Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. (“Ono”), today announced an option and asset purchase agreement through which Ono gains the exclusive option to purchase Equillium's rights to itolizumab, a first-in-class monoclonal antibody targeting CD6. These rights include all therapeutic indications and the rights to commercialize itolizumab in the United States, Canada, Australia, and New Zealand.

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Metacrine

NEW YORK,, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. ("Equillium" or the "Company") (NASDAQ: EQ), in connection with its takeover of Metacrine, Inc. (Metacrine) (NASDAQ: MTCR). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the Metacrine net cash delivered at closing, which is estimated to be approximately $26 million.

SHAREHOLDER ALERT: Weiss Law Investigates Equillium, Inc.

NEW YORK , Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. ("Metacrine" or the "Company") (NASDAQ: MTCR), in connection with the acquisition of the Company by Equillium, Inc. ("Equillium") (NASDAQ: EQ). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26 million.

SHAREHOLDER ALERT: Weiss Law Investigates Metacrine, Inc.

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2022 and provided an update on its clinical development programs.

Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif.--( BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that a poster presentation was given over the weekend at ACR Convergence, the annual meeting of the American College of Rheumatology. The presentation highlighted that levels of urinary soluble ALCAM (sALCAM) could be a potential biomarker of disease severity in lupus nephritis (LN) and indicative of a patient's response to treatment. The meeting, the world's premier rheumatology conference, is taking place November 10 – 14, 2022 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022

Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata

Equillium to Present at Two Upcoming Investor Conferences

Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Metacrine Inc. (NasdaqCM: MTCR) (the “Company”) with Equillium, Inc. (NasdaqGM: EQ) in an all-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction undervalues the Comp

METACRINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCR

Clinical-stage biotechnology firm Equillium (NASDAQ: EQ ), which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data regarding itolizumab. A monoclonal antibody, itolizumab aims to provide positive outcomes for patients suffering from lupus nephritis (or LN).

Why Is Equillium (EQ) Stock Soaring 20% Today?

Shares of Equillium Inc. EQ, -3.98% gained 12.9% in premarket trading on Tuesday after the company shared a batch of interim data from an early stage trial evaluating its experimental treatment in 13 people with lupus nephritis. Equillium said 83% of the participants enrolled in the study achieved complete or partial response, and about two-thirds had a 80% reduction in urine protein creatinine ratio by week 28.

Equillium's stock is up 12% after sharing early data about its investigational lupus treatment

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced interim results from the Type B portion of the EQUALISE study evaluating itolizumab, a first-in-class anti-CD6 monoclonal antibody selectively targeting the CD6-ALCAM pathway, in patients with lupus nephritis (LN). “Despite recently approved therapies, 6

Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis

Rocket Pharma

STORE Capital

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Equillium, Inc. (NASDAQ: EQ) 's  merger with Metacrine Inc. If you are an Equillium shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT

Channeladvisor

Signify Health

NEW YORK , Sept. 19, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ChannelAdvisor Corporation (NYSE: ECOM) 's  sale to CommerceHub for $23.10 per share in cash.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that an abstract was accepted for presentation at ACR Convergence, the annual meeting of the American College of Rheumatology. The meeting, the world's premier virtual rheumatology experience, will take place online November 10 – 14, 2022 at the Pennsylv

Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Equillium, Inc. (NASDAQ: EQ) and Metacrine Inc. is fair to Equillium shareholders. Halper Sadeh encourages Equillium shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Equillium and its board violated the federa

EQ Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Equillium, Inc. is Fair to Shareholders

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ) and Metacrine Inc. (Nasdaq: MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024. The transaction has been approved by the boards of directors of both

Equillium to Acquire Metacrine in All-Stock Transaction

Revenue Increases 19% Over the Previous Quarter With Data Revenue Increasing Over 56% TORONTO, ON / ACCESSWIRE / August 19, 2022 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in geospatial data and artificial intelligence driven software, announced its financial results today for the second quarter ended June 30, 2022. Announcing the Company's highest second quarter revenue in over a decade, EQ reported revenue of over $3.2 million, an increase of 19% over the previous quarter and an increase of 8% compared to the second quarter of 2021.

EQ Inc. Reports Strongest Second Quarter in Over a Decade

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2022 and provided an update on its clinical development programs. “The second quarter focused largely on the execution of our development programs with itolizumab and our plans to advance the clinical development

Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 3rd Annual Cytokine-Based Drug Development Summit. The presentation highlights Equillium's multi-cytokine inhibitor technology and platform, and applications of cytokine technology beyond oncology. Data on the platform, including th

Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs. “It's been a transformative start to the year, leading to significant enhancements in how we are building value going forward,” said B

Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates

News for Equillium Inc Stock (EQ)